| Year |
Citation |
Score |
| 2023 |
Li L, Hu X, Nkwocha J, Sharma K, Kmieciak M, Mann H, Zhou L, Grant S. Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells. Cellular Oncology (Dordrecht). PMID 37126127 DOI: 10.1007/s13402-023-00817-6 |
0.303 |
|
| 2023 |
Bouligny IM, Maher KR, Grant S. Augmenting Venetoclax Activity Through Signal Transduction in AML. Journal of Cellular Signaling. 4: 1-12. PMID 36911757 DOI: 10.33696/signaling.4.085 |
0.336 |
|
| 2023 |
Hu X, Li L, Nkwocha J, Sharma K, Zhou L, Grant S. Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells. Hematology Reports. 15: 91-100. PMID 36810553 DOI: 10.3390/hematolrep15010010 |
0.344 |
|
| 2023 |
Satta T, Li L, Chalasani SL, Hu X, Nkwocha J, Sharma K, Kmieciak M, Rahmani M, Zhou L, Grant S. Dual mTORC1/2 inhibition synergistically enhances AML cell death in combination with the BCL2 antagonist venetoclax. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36652560 DOI: 10.1158/1078-0432.CCR-22-2729 |
0.342 |
|
| 2022 |
Leng Y, Hu X, Li L, Nkwocha J, Satta T, Sharma K, Kmeiciak M, Zhou H, Zhang Z, Zhou L, Chen W, Grant S. MECHANISMS UNDERLYING SYNERGISM BETWEEN CIRCULARIZED TRAIL (CPT) AND BORTEZOMIB IN BORTEZOMIB-SENSITIVE OR -RESISTANT MYELOMA CELLS. Hematological Oncology. PMID 35789025 DOI: 10.1002/hon.3045 |
0.449 |
|
| 2021 |
Zhou L, Pei X, Zhang Y, Ning Y, Li L, Hu X, Chalasani SL, Sharma K, Nkwocha J, Yu J, Bandyopadhyay D, Sebti SM, Grant S. Chk1 inhibition potently blocks STAT3 tyrosine705 phosphorylation, DNA binding activity, and activation of downstream targets in human multiple myeloma cells. Molecular Cancer Research : McR. PMID 34782371 DOI: 10.1158/1541-7786.MCR-21-0366 |
0.447 |
|
| 2021 |
Zhou L, Zhang Y, Meads MB, Dai Y, Ning Y, Hu X, Li L, Sharma K, Nkwocha J, Parker R, Bui D, McCarter J, Kramer L, Purcell C, Sudalagunta P, ... ... Grant S, et al. LCL161 interacts synergystically with panobinostat in multiple myeloma cells through non-canonical NF-κB- and caspase-8-dependent mechanisms. Blood Advances. PMID 34464977 DOI: 10.1182/bloodadvances.2020003597 |
0.449 |
|
| 2020 |
Grant S. Recruiting TP53 to target chronic myeloid leukemia stem cells. Haematologica. 105: 1172-1174. PMID 32358077 DOI: 10.3324/Haematol.2019.246306 |
0.306 |
|
| 2020 |
Yazbeck V, McConnell I, Harris E, Lownick J, Sindel A, Sabo R, Chesney A, Lai G, Mauro A, Cain C, Salloum F, Grant S, Zweit J, Windle J, Grossman S. Abstract B41: Modeling marginal zone lymphomagenesis Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-B41 |
0.397 |
|
| 2019 |
Zhang Y, Zhou L, Bandyopadhyay D, Sharma K, Allen AJ, Kmieciak M, Grant S. The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358538 DOI: 10.1158/1078-0432.CCR-18-3788 |
0.422 |
|
| 2019 |
Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. Retraction: and Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells. Molecular Cancer Therapeutics. 18: 1181. PMID 31160511 DOI: 10.1158/1535-7163.MCT-19-0471 |
0.32 |
|
| 2019 |
Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells and . Molecular Cancer Therapeutics. 18: 1180. PMID 31160510 DOI: 10.1158/1535-7163.MCT-19-0470 |
0.319 |
|
| 2019 |
Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells and . Molecular Cancer Therapeutics. 18: 1179. PMID 31160509 DOI: 10.1158/1535-7163.MCT-19-0469 |
0.325 |
|
| 2019 |
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, ... ... Grant S, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. PMID 31123034 DOI: 10.3324/Haematol.2018.205534 |
0.529 |
|
| 2019 |
Dasmahapatra G, Nguyen TK, Dent P, Grant S. Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]. Leukemia Research. PMID 31079870 DOI: 10.1016/J.Leukres.2019.03.002 |
0.417 |
|
| 2019 |
Yazbeck V, McConnell I, Lownik J, Sindel A, Sabo R, Chesney A, Lai G, Mauro A, Zweit J, Martin R, Conrad D, Grant S, Windle J, Grossman S. Abstract 4634: Mouse model for nodal marginal zone lymphoma Cancer Research. 79: 4634-4634. DOI: 10.1158/1538-7445.Am2019-4634 |
0.393 |
|
| 2018 |
Nguyen T, Parker R, Zhang Y, Hawkins E, Kmieciak M, Craun W, Grant S. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. Bmc Cancer. 18: 1129. PMID 30445933 DOI: 10.1186/s12885-018-5018-x |
0.362 |
|
| 2018 |
Dastur A, Choi A, Costa C, Yin X, Williams AF, McClanaghan JD, Greenberg M, Roderick JE, Patel NU, Boisvert JL, McDermott U, Garnett MJ, Almenara J, Grant S, Rizzo K, et al. NOTCH1 represses MCL-1 levels in GSI-resistant T-ALL, making them susceptible to ABT-263. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30224339 DOI: 10.1158/1078-0432.Ccr-18-0867 |
0.321 |
|
| 2018 |
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, ... ... Grant S, et al. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 18: 569-575.e1. PMID 30122201 DOI: 10.1016/J.Clml.2018.05.023 |
0.415 |
|
| 2018 |
Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, Leverson JD, Sampath D, Ferreira-Gonzalez A, Grant S. Co-targeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Research. PMID 29559471 DOI: 10.1158/0008-5472.Can-17-3024 |
0.588 |
|
| 2018 |
Sindel A, McConnell I, Windle J, Sabo R, Chesney A, Lai G, Mauro A, Al-Juhaishi T, Rahmani M, Zweit J, Grant S, Grossman S, Yazbeck VY. Role of the PI3K Pathway in the Pathogenesis of Marginal Zone Lymphoma Blood. 132: 4125-4125. DOI: 10.1182/Blood-2018-99-111284 |
0.383 |
|
| 2018 |
Grant S, Rahmani M, Nkwocha J, Kmieciak M, Leverson J, Sampath D. Abstract LB-081: Co-targeting BCL-2 and PI3K potently induces BAXdependent mitochondrial apoptosis in AML Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-081 |
0.586 |
|
| 2018 |
Zhou L, Zhang Y, Sharma K, McCarter J, Craun W, Grant S. Abstract 4836: Targeting transcriptional regulation in multiple myeloma with a covalent CDK7 inhibitor THZ1 Cancer Research. 78: 4836-4836. DOI: 10.1158/1538-7445.Am2018-4836 |
0.545 |
|
| 2017 |
Bryant KG, Chae YC, Martinez RL, Gordon JC, Elokely KM, Kossenkov AV, Grant S, Childers WE, Abou-Gharbia M, Altieri DC. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy. Oncotarget. 8: 112184-112198. PMID 29348817 DOI: 10.18632/Oncotarget.23097 |
0.406 |
|
| 2017 |
Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant S. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. British Journal of Cancer. PMID 29241222 DOI: 10.1038/Bjc.2017.432 |
0.365 |
|
| 2017 |
Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant S. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget. 8: 59476-59491. PMID 28938651 DOI: 10.18632/Oncotarget.19761 |
0.497 |
|
| 2017 |
Grant S. Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies. Leukemia & Lymphoma. 1-8. PMID 28838268 DOI: 10.1080/10428194.2017.1366999 |
0.368 |
|
| 2017 |
Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Oncotarget. PMID 28416758 DOI: 10.18632/Oncotarget.15649 |
0.535 |
|
| 2017 |
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, ... ... Grant S, et al. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leukemia & Lymphoma. 1-9. PMID 28103725 DOI: 10.1080/10428194.2016.1276287 |
0.352 |
|
| 2017 |
Nguyen T, Parker R, Hawkins E, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S. Abstract 2018: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occurin vitroandin vivoand proceed through multiple mechanisms Cancer Research. 77: 2018-2018. DOI: 10.1158/1538-7445.Am2017-2018 |
0.428 |
|
| 2016 |
Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. PMID 27806331 DOI: 10.18632/Oncotarget.12969 |
0.491 |
|
| 2016 |
Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 291: 20823. PMID 27664064 DOI: 10.1074/jbc.A116.803444 |
0.349 |
|
| 2016 |
Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. Journal of Hematology & Oncology. 9: 73. PMID 27557643 DOI: 10.1186/S13045-016-0304-Z |
0.342 |
|
| 2016 |
Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S. Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry. 291: 17535. PMID 27543593 DOI: 10.1074/jbc.A109.095208 |
0.334 |
|
| 2016 |
Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia. PMID 27055874 DOI: 10.1038/Leu.2016.7 |
0.539 |
|
| 2016 |
Shafer D, Grant S. Update on rational targeted therapy in AML. Blood Reviews. PMID 26972558 DOI: 10.1016/J.Blre.2016.02.001 |
0.42 |
|
| 2016 |
Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Rahmani M, Povirk L, Chalasani S, Berger AJ, Dai Y, ... Grant S, et al. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood. PMID 26851293 DOI: 10.1182/Blood-2015-06-653717 |
0.551 |
|
| 2016 |
Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... Grant S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356 |
0.509 |
|
| 2016 |
Turner JG, Kashyap T, Dawson JL, Gomez JA, Bauer A, Grant S, Dai Y, Shain KH, Meads MB, Landesman Y, Sullivan DM. Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma Blood. 128: 3299-3299. DOI: 10.1182/Blood.V128.22.3299.3299 |
0.503 |
|
| 2016 |
Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Turner J, Sullivan D, Dai Y, Grant S. Abstract 3020: Targeting both canonical and non-canonical NF-kB pathways by the IAP antagonist birinapant potentiates bortezomib anti-myeloma activity Cancer Research. 76: 3020-3020. DOI: 10.1158/1538-7445.Am2016-3020 |
0.546 |
|
| 2015 |
Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica. PMID 26452980 DOI: 10.1182/Blood.V126.23.3676.3676 |
0.556 |
|
| 2015 |
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, ... ... Grant S, et al. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446942 DOI: 10.1158/1078-0432.Ccr-15-1076 |
0.367 |
|
| 2015 |
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, ... ... Grant S, et al. Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas. Leukemia & Lymphoma. 1-30. PMID 26284612 DOI: 10.3109/10428194.2015.1075019 |
0.302 |
|
| 2015 |
Sperlazza J, Rahmani M, Beckta J, Aust M, Hawkins E, Wang SZ, Zhu SZ, Podder S, Dumur C, Archer K, Grant S, Ginder GD. Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation. Blood. PMID 26265695 DOI: 10.1182/Blood-2015-03-631606 |
0.578 |
|
| 2015 |
Grant S. ATRA and ATO team up against NPM1. Blood. 125: 3369-71. PMID 26022051 DOI: 10.1182/Blood-2015-04-636217 |
0.35 |
|
| 2015 |
Yazbeck VY, Grant S. Romidepsin for the treatment of non-Hodgkin's lymphoma. Expert Opinion On Investigational Drugs. 24: 965-79. PMID 25936363 DOI: 10.1517/13543784.2015.1041586 |
0.426 |
|
| 2015 |
Dai Y, Grant S. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy. 11: 416-8. PMID 25700997 DOI: 10.1080/15548627.2014.998892 |
0.437 |
|
| 2015 |
Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L, Eklund EA. Targeting novel signaling pathways for resistant acute myeloid leukemia. Molecular Genetics and Metabolism. 114: 397-402. PMID 25533111 DOI: 10.1016/J.Ymgme.2014.11.017 |
0.364 |
|
| 2015 |
Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⺠leukemia cells. Leukemia Research. 39: 65-71. PMID 25465126 DOI: 10.1016/J.Leukres.2014.10.009 |
0.517 |
|
| 2015 |
Kiebala M, Skalska J, Casulo C, Brookes PS, Peterson DR, Hilchey SP, Dai Y, Grant S, Maggirwar SB, Bernstein SH. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Experimental Hematology. 43: 89-99. PMID 25448488 DOI: 10.1016/J.Exphem.2014.10.004 |
0.481 |
|
| 2015 |
Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y, Grant S. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia. 29: 807-18. PMID 25283841 DOI: 10.1038/Leu.2014.296 |
0.508 |
|
| 2015 |
Hamed HA, Tavallai S, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. Journal of Cellular Physiology. 230: 131-9. PMID 24911215 DOI: 10.1002/Jcp.24689 |
0.499 |
|
| 2015 |
Sullivan DM, Kashyap T, Dawson JL, Landesman Y, Grant S, Shain KH, Dai Y, Kauffman M, Shacham S, Turner JG. Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma Blood. 126: 3048-3048. DOI: 10.1182/Blood.V126.23.3048.3048 |
0.5 |
|
| 2015 |
Turner JG, Dawson JL, Cubitt CL, Baluglo E, Grant S, Dai Y, Shain KH, Dalton WS, Shacham S, Senapedis W, Sullivan DM. Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma Blood. 126: 1818-1818. DOI: 10.1182/Blood.V126.23.1818.1818 |
0.488 |
|
| 2015 |
Dai Y, Chen S, Zhou L, Zhang Y, Leng Y, Pei X, Lin H, Jones R, Robert O, Grant S. Abstract B15: Targeting SQSTM1/p62 induces cargo-loading failure and converts autophagy to apoptosis via NBK/Bik in human multiple myeloma cells. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-B15 |
0.477 |
|
| 2015 |
Zhou L, Chen S, Zhang Y, Leng Y, Li L, Lin H, Kmieciak M, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y, Grant S. Abstract LB-258: The NAE inhibitor pevonedistat (MLN4924) interacts with the HDAC inhibitor belinostat via disruption of the intra-S checkpoint and both HR and NHEJ DNA repair in AML cells Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-258 |
0.525 |
|
| 2014 |
Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opinion On Pharmacotherapy. 15: 2443-59. PMID 25263936 DOI: 10.1517/14656566.2014.965142 |
0.369 |
|
| 2014 |
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, ... ... Grant S, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5652-62. PMID 25248382 DOI: 10.1158/1078-0432.Ccr-14-0805 |
0.339 |
|
| 2014 |
Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Molecular Cancer Therapeutics. 13: 2886-97. PMID 25239935 DOI: 10.1158/1535-7163.Mct-14-0220 |
0.565 |
|
| 2014 |
Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 124: 2687-97. PMID 25208888 DOI: 10.1182/Blood-2014-03-564534 |
0.484 |
|
| 2014 |
Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. Plos One. 9: e103015. PMID 25181509 DOI: 10.1371/Journal.Pone.0103015 |
0.618 |
|
| 2014 |
Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P. Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. Molecular Cancer Therapeutics. 13: 2384-98. PMID 25103559 DOI: 10.1158/1535-7163.Mct-14-0172 |
0.53 |
|
| 2014 |
Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4849-60. PMID 25070836 DOI: 10.1158/1078-0432.Ccr-14-0034 |
0.487 |
|
| 2014 |
Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S. Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Molecular and Cellular Biology. 34: 3435-49. PMID 25002530 DOI: 10.1128/Mcb.01383-13 |
0.407 |
|
| 2014 |
Vachhani P, Bose P, Rahmani M, Grant S. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiological Genomics. 46: 448-56. PMID 24824212 DOI: 10.1152/Physiolgenomics.00173.2013 |
0.537 |
|
| 2014 |
Grant S. Bortezomib resistance and MUC1 in myeloma. Blood. 123: 2910-2. PMID 24810626 DOI: 10.1182/Blood-2014-03-563882 |
0.466 |
|
| 2014 |
Cazanave SC, Wang X, Zhou H, Rahmani M, Grant S, Durrant DE, Klaassen CD, Yamamoto M, Sanyal AJ. Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis. Cell Death and Differentiation. 21: 1303-12. PMID 24769730 DOI: 10.1038/Cdd.2014.49 |
0.465 |
|
| 2014 |
Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacology & Therapeutics. 143: 323-36. PMID 24769080 DOI: 10.1016/J.Pharmthera.2014.04.004 |
0.429 |
|
| 2014 |
Roberts JL, Booth L, Conley A, Cruickshanks N, Malkin M, Kukreja RC, Grant S, Poklepovic A, Dent P. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biology & Therapy. 15: 758-67. PMID 24651037 DOI: 10.4161/Cbt.28553 |
0.496 |
|
| 2014 |
Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. Plos One. 9: e89064. PMID 24594907 DOI: 10.1371/Journal.Pone.0089064 |
0.468 |
|
| 2014 |
Tavallai S, Hamed HA, Grant S, Poklepovic A, Dent P. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biology & Therapy. 15: 578-85. PMID 24556916 DOI: 10.4161/Cbt.28163 |
0.453 |
|
| 2014 |
Nguyen TK, Grant S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Molecular Cancer Therapeutics. 13: 662-74. PMID 24362465 DOI: 10.1158/1535-7163.Mct-13-0714 |
0.508 |
|
| 2014 |
Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A, Dent P. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Molecular Pharmacology. 85: 408-19. PMID 24353313 DOI: 10.1124/Mol.113.090043 |
0.512 |
|
| 2014 |
Booth L, Roberts JL, Conley A, Cruickshanks N, Ridder T, Grant S, Poklepovic A, Dent P. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biology & Therapy. 15: 305-16. PMID 24351423 DOI: 10.4161/Cbt.27309 |
0.524 |
|
| 2014 |
Dai Y, Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Hui L, Grant S. HDAC Inhibitors Reciprocally Interacts the Wee1 Inhibitor AZD1775 to Abrogate Both the G1/S and G2/M Checkpoints Via Chk1-Related cdc2/Cdk1 Threonine 14 Dephosphorylation in AML Cells Blood. 124: 997-997. DOI: 10.1182/Blood.V124.21.997.997 |
0.465 |
|
| 2014 |
Pei X, Sanderson MW, Youssefian LE, Felthousen J, Kramer LB, Dai Y, Grant S. Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism Blood. 124: 4763-4763. DOI: 10.1182/Blood.V124.21.4763.4763 |
0.527 |
|
| 2014 |
Holkova B, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Singh AG, Dean A, Conine S, Sankala H, Roberts JD, ... ... Grant S, et al. Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results Blood. 124: 3050-3050. DOI: 10.1182/Blood.V124.21.3050.3050 |
0.36 |
|
| 2014 |
Turner JG, Dawson JL, Grant S, Shain KH, Dai Y, Cubitt C, Baz R, Nishihori T, Kauffman M, Shacham S, Sullivan DM. Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma Blood. 124: 2084-2084. DOI: 10.1182/Blood.V124.21.2084.2084 |
0.504 |
|
| 2014 |
Rahmani M, Aust MM, Grant S. Abstract LB-225: E2F1 potentiates proteasome inhibition-mediated cell death in leukemia cells through induction of Noxa Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-225 |
0.589 |
|
| 2014 |
Cruickshanks NA, Hamed HA, Booth LA, Tavallai S, Sajithlal GB, Grant S, Poklepovic A, Dent P. Abstract 796: Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy Cancer Research. 74: 796-796. DOI: 10.1158/1538-7445.Am2014-796 |
0.473 |
|
| 2014 |
Dai Y, Chen S, Zhou L, Zhang Y, Leng Y, Pei X, Lin H, Orlowski RZ, Grant S. Abstract 4600: P-TEFb is a therapeutic target in human bortezomib-resistant multiple myeloma cells Cancer Research. 74: 4600-4600. DOI: 10.1158/1538-7445.Am2014-4600 |
0.407 |
|
| 2014 |
Zhang Y, Zhou L, Chen S, Kmieciak M, Lin H, Dai Y, Grant S. Abstract 4556: A therapeutic strategy combining the Wee1 inhibitor MK1775 with HDAC inhibitors targets both p53 wild-type or mutant AML cells Cancer Research. 74: 4556-4556. DOI: 10.1158/1538-7445.Am2014-4556 |
0.529 |
|
| 2014 |
Booth LA, Cruickshanks NA, Sajithlal GB, Hamed HA, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Abstract 2690: Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells Cancer Research. 74: 2690-2690. DOI: 10.1158/1538-7445.Am2014-2690 |
0.548 |
|
| 2014 |
Nguyen TK, Grant S. Abstract 2686: The CDK inhibitor dinaciclib (SCH727965) inhibits the unfolded protein response (UPR) through a CDK1- and CDK5-dependent mechanism Cancer Research. 74: 2686-2686. DOI: 10.1158/1538-7445.Am2014-2686 |
0.513 |
|
| 2014 |
Turner JG, Shain KH, Dai Y, Dawson JL, Cubitt CL, Shacham S, Kauffman M, Grant S, Sullivan DM. Abstract 1772: Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy Cancer Research. 74: 1772-1772. DOI: 10.1158/1538-7445.Am2014-1772 |
0.465 |
|
| 2014 |
Meier J, Raza A, Yamada A, Dai Y, Chen S, Grant S, Takabe K, Larner A. 107 Cytokine. 70: 53. DOI: 10.1016/J.Cyto.2014.07.114 |
0.432 |
|
| 2013 |
Hamed HA, Das SK, Sokhi UK, Park MA, Cruickshanks N, Archer K, Ogretmen B, Grant S, Sarkar D, Fisher PB, Dent P. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biology & Therapy. 14: 1039-49. PMID 24025359 DOI: 10.4161/Cbt.26110 |
0.345 |
|
| 2013 |
Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biology & Therapy. 14: 982-96. PMID 24025251 DOI: 10.4161/Cbt.26234 |
0.486 |
|
| 2013 |
Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leukemia Research Reports. 2: 18-20. PMID 23977454 DOI: 10.1016/J.Lrr.2013.02.001 |
0.376 |
|
| 2013 |
Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leukemia Research Reports. 2: 12-14. PMID 23977453 DOI: 10.1016/j.lrr.2012.11.006 |
0.365 |
|
| 2013 |
Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biology & Therapy. 14: 458-65. PMID 23917378 DOI: 10.4161/Cbt.24424 |
0.474 |
|
| 2013 |
Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Molecular Pharmacology. 84: 562-71. PMID 23877009 DOI: 10.1124/Mol.113.088005 |
0.542 |
|
| 2013 |
Liu K, Zhang D, Chojnacki J, Du Y, Fu H, Grant S, Zhang S. Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. Organic & Biomolecular Chemistry. 11: 4757-63. PMID 23784627 DOI: 10.1039/C3Ob40595H |
0.422 |
|
| 2013 |
Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. Journal of Cellular Physiology. 228: 1996-2005. PMID 23674352 DOI: 10.1002/Jcp.24362 |
0.55 |
|
| 2013 |
Hamed HA, Yacoub A, Park MA, Archer K, Das SK, Sarkar D, Grant S, Fisher PB, Dent P. Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells. Molecular Pharmacology. 84: 171-81. PMID 23661648 DOI: 10.1124/Mol.113.086553 |
0.34 |
|
| 2013 |
Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opinion On Investigational Drugs. 22: 723-38. PMID 23647051 DOI: 10.1517/13543784.2013.789859 |
0.512 |
|
| 2013 |
Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY, Grant S. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Molecular Cancer Therapeutics. 12: 878-89. PMID 23536721 DOI: 10.1158/1535-7163.Mct-12-0902 |
0.496 |
|
| 2013 |
Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. Plos One. 8: e56471. PMID 23437140 DOI: 10.1371/Journal.Pone.0056471 |
0.416 |
|
| 2013 |
Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. British Journal of Haematology. 161: 43-56. PMID 23360303 DOI: 10.1111/Bjh.12206 |
0.536 |
|
| 2013 |
Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Research. 73: 1340-51. PMID 23243017 DOI: 10.1158/0008-5472.Can-12-1365 |
0.568 |
|
| 2013 |
Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, Emdad L, Pellecchia M, Sarkar D, Fisher PB. MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Research. 73: 844-54. PMID 23233738 DOI: 10.1158/0008-5472.Can-12-1681 |
0.408 |
|
| 2013 |
Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 404-14. PMID 23204129 DOI: 10.1158/1078-0432.Ccr-12-2799 |
0.455 |
|
| 2013 |
Rahmani M, Aust M, Wallace L, Grant S. Inhibition Of PI3K/mTOR By BEZ235 Dramatically Potentiates Panobinostat-Induced Lethality In Diffuse Large B-Cell Lymphoma Through Multiple Mechanisms Blood. 122: 817-817. DOI: 10.1182/Blood.V122.21.817.817 |
0.589 |
|
| 2013 |
Chen S, Dai Y, Zhang Y, Zhou L, Lin H, Pei X, Orlowski RZ, Grant S. Bim-Targeting Therapy Circumvents Adaptive Bortezomib-Resistance In Myeloma Through a Novel Cross-Link Between Autophagy and Apoptosis Blood. 122: 601-601. DOI: 10.1182/Blood.V122.21.601.601 |
0.53 |
|
| 2013 |
Holkova B, Kmieciak M, Bose P, Barr PM, Tombes MB, Shrader E, Cebula E, Pierce E, Herr MM, Sankala H, Feng C, Fisher RI, Grant S, Friedberg JW. Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas Blood. 122: 4375-4375. DOI: 10.1182/Blood.V122.21.4375.4375 |
0.363 |
|
| 2013 |
Dasmahapatra GP, Patel H, Nguyen T, Benson E, Grant S. Abstract 588: PLK1 inhibitors interact synergistically with HDAC inhibitors in IM-sensitive or -resistant BCR/ABL+leukemia cellsin vitroandin vivo. Cancer Research. 73: 588-588. DOI: 10.1158/1538-7445.Am2013-588 |
0.588 |
|
| 2013 |
Das SK, Kegelman TP, Santhekadur PK, Dasgupta S, Dent P, Grant S, Emdad L, Sarkar D, Fisher PB, Pellecchia M. Abstract 3902: MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Research. 73: 3902-3902. DOI: 10.1158/1538-7445.Am2013-3902 |
0.383 |
|
| 2013 |
Chen S, Kmieciak M, Zhou L, Lin H, Pei X, Dai Y, Grant S. Abstract 3420: The novel Chk1 inhibitor MK8776 sensitizes AML cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Cancer Research. 73: 3420-3420. DOI: 10.1158/1538-7445.Am2013-3420 |
0.49 |
|
| 2013 |
Zhou L, Chen S, Lin H, Pei X, Aust MM, Rahmani M, Rosato R, Dai Y, Grant S. Abstract 3346: A20/TNFAIP3, a novel target of histone deacetylase inhibitor-induced NF-κB activation, functionally disables the extrinsic apoptotic pathway in human leukemia cells. Cancer Research. 73: 3346-3346. DOI: 10.1158/1538-7445.Am2013-3346 |
0.417 |
|
| 2013 |
Iyer SP, Mejia J, Rosato AE, Grant S, Rosato RR. Abstract 2960: Flavopiridol-mediated multiple modulatory effects synergistically increase sensitivity to TRAIL-induced cell death in human leukemia cells. Cancer Research. 73: 2960-2960. DOI: 10.1158/1538-7445.Am2013-2960 |
0.5 |
|
| 2012 |
Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). Epigenomics. 4: 571-89. PMID 23130838 DOI: 10.2217/epi.12.52 |
0.328 |
|
| 2012 |
Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Advances in Cancer Research. 116: 199-237. PMID 23088872 DOI: 10.1016/B978-0-12-394387-3.00006-9 |
0.34 |
|
| 2012 |
Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biology & Therapy. 13: 1501-11. PMID 22990204 DOI: 10.4161/Cbt.22275 |
0.514 |
|
| 2012 |
Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, Dent P. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Molecular Pharmacology. 82: 1217-29. PMID 22989520 DOI: 10.1124/Mol.112.081539 |
0.514 |
|
| 2012 |
Yaseen A, Chen S, Hock S, Rosato R, Dent P, Dai Y, Grant S. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Molecular Pharmacology. 82: 1030-41. PMID 22923501 DOI: 10.1124/Mol.112.079624 |
0.536 |
|
| 2012 |
Grant S. FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators. The Journal of Clinical Investigation. 122: 3048-51. PMID 22886299 DOI: 10.1172/Jci64412 |
0.389 |
|
| 2012 |
Harada H, Grant S. Targeting the regulatory machinery of BIM for cancer therapy. Critical Reviews in Eukaryotic Gene Expression. 22: 117-29. PMID 22856430 DOI: 10.1615/Critreveukargeneexpr.V22.I2.40 |
0.436 |
|
| 2012 |
Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Research. 72: 4225-37. PMID 22693249 DOI: 10.1158/0008-5472.Can-12-1118 |
0.556 |
|
| 2012 |
Holkova B, Grant S. Proteasome inhibitors in mantle cell lymphoma. Best Practice & Research. Clinical Haematology. 25: 133-41. PMID 22687449 DOI: 10.1016/J.Beha.2012.04.007 |
0.436 |
|
| 2012 |
Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S, Dent P. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biology & Therapy. 13: 793-803. PMID 22673740 DOI: 10.4161/Cbt.20562 |
0.522 |
|
| 2012 |
Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Molecular Pharmacology. 82: 322-32. PMID 22596349 DOI: 10.1124/Mol.112.078907 |
0.48 |
|
| 2012 |
Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood. 119: 6089-98. PMID 22446485 DOI: 10.1182/Blood-2011-09-378141 |
0.568 |
|
| 2012 |
Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Molecular Cancer Therapeutics. 11: 1122-32. PMID 22411899 DOI: 10.1158/1535-7163.Mct-12-0021 |
0.576 |
|
| 2012 |
Tang Y, Yacoub A, Hamed HA, Poklepovic A, Tye G, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biology & Therapy. 13: 567-74. PMID 22406992 DOI: 10.4161/Cbt.19771 |
0.537 |
|
| 2012 |
Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, Dent P. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Molecular Pharmacology. 81: 748-58. PMID 22357666 DOI: 10.1124/Mol.112.077586 |
0.453 |
|
| 2012 |
Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biology & Therapy. 13: 224-36. PMID 22354011 DOI: 10.4161/Cbt.13.4.18877 |
0.468 |
|
| 2012 |
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, ... ... Grant S, et al. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemotherapy and Pharmacology. 69: 1657-67. PMID 22349810 DOI: 10.1007/S00280-012-1839-5 |
0.481 |
|
| 2012 |
Tang Y, Dai Y, Grant S, Dent P. Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biology & Therapy. 13: 379-88. PMID 22313687 DOI: 10.4161/Cbt.19240 |
0.554 |
|
| 2012 |
Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Molecular Pharmacology. 81: 527-40. PMID 22219388 DOI: 10.1124/Mol.111.076851 |
0.533 |
|
| 2012 |
Liu K, Rao W, Parikh H, Li Q, Guo TL, Grant S, Kellogg GE, Zhang S. 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization. European Journal of Medicinal Chemistry. 47: 125-37. PMID 22074985 DOI: 10.1016/J.Ejmech.2011.10.031 |
0.474 |
|
| 2012 |
Rosato R, Hock S, Dent P, Dai Y, Grant S. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. Leukemia Research. 36: 491-8. PMID 22074700 DOI: 10.1016/J.Leukres.2011.10.020 |
0.505 |
|
| 2012 |
Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP, Curiel DT, Grant S, Dent P, Reed JC, Pellecchia M, et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. Journal of Cellular Physiology. 227: 2145-53. PMID 21780116 DOI: 10.1002/Jcp.22947 |
0.326 |
|
| 2012 |
Bhutia SK, Das SK, Kegelman TP, Azab B, Dash R, Su ZZ, Wang XY, Rizzi F, Bettuzzi S, Lee SG, Dent P, Grant S, Curiel DT, Sarkar D, Fisher PB. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. Journal of Cellular Physiology. 227: 1805-13. PMID 21732348 DOI: 10.1002/Jcp.22904 |
0.372 |
|
| 2012 |
Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene. 31: 537-51. PMID 21725353 DOI: 10.1038/Onc.2011.267 |
0.359 |
|
| 2012 |
Holkova B, Perkins EB, Bose P, Sullivan DM, Baz R, Tombes MB, Shrader E, Ramakrishnan V, Wan W, Sankala H, Kmieciak M, Roberts JD, Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib. Blood. 120: 2959-2959. DOI: 10.1182/Blood.V120.21.2959.2959 |
0.385 |
|
| 2012 |
Dasmahapatra G, Patel H, Al-Khafaji JT, Fisher RI, Friedberg JW, Grant S. The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib. Blood. 120: 2765-2765. DOI: 10.1182/Blood.V120.21.2765.2765 |
0.583 |
|
| 2012 |
Holkova B, Shea TC, Bose P, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts JD, Grant S. Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma Blood. 120: 1794-1794. DOI: 10.1182/Blood.V120.21.1794.1794 |
0.379 |
|
| 2012 |
Skalska J, Kiebala MM, Hilchey SP, Dai Y, Grant S, Brookes PS, Peterson DR, Maggirwar SB, Bernstein SH. The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent Blood. 120: 1658-1658. DOI: 10.1182/Blood.V120.21.1658.1658 |
0.466 |
|
| 2012 |
Azab B, Dash R, Das S, Bhutia S, Shen X, Quinn B, Dasgupta S, Dent P, Dmitriev I, Wang X, Curiel D, Grant S, Pellecchia M, Reed J, Sarkar D, et al. Abstract 61: A new serotype chimera Cancer Terminator Virus (Ad.5/3-CTV) expands the efficiency and specificity of prostate cancer gene transfer and therapy Cancer Research. 72: 61-61. DOI: 10.1158/1538-7445.Am2012-61 |
0.347 |
|
| 2012 |
Yaseen A, Dai Y, Rosato R, Grant S. Abstract 4706: Resveratrol potentiates the lethality of HDAC inhibitors in acute myelogenous leukemia cells Cancer Research. 72: 4706-4706. DOI: 10.1158/1538-7445.Am2012-4706 |
0.541 |
|
| 2012 |
Pei X, Dai Y, Felthousen J, Chen S, Wang L, Takabatake Y, Youssefian LE, Bodie WW, Kramer L, Grant S. Abstract 4667: Simultaneous Chk1 and MEK1/2 inhibition circumvents Mcl-1 anti-apoptotic function and bortezomib resistance in human multiple myeloma cells Cancer Research. 72: 4667-4667. DOI: 10.1158/1538-7445.Am2012-4667 |
0.529 |
|
| 2012 |
Dai Y, Chen S, Wang L, Pei X, Myers J, Schwartz D, Thompson N, Larsen D, Richey J, Su F, Orlowski RZ, Grant S. Abstract 4649: Nbk/Bik induced by flavopiridol switches GX15-070-induced autophagy to apoptosis in human multiple myeloma cells Cancer Research. 72: 4649-4649. DOI: 10.1158/1538-7445.Am2012-4649 |
0.526 |
|
| 2011 |
Holkova B, Grant S. Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies. Expert Review of Hematology. 4: 483-6. PMID 21939415 DOI: 10.1586/Ehm.11.50 |
0.373 |
|
| 2011 |
Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, Grant S. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood. 118: 5189-200. PMID 21911831 DOI: 10.1182/Blood-2011-02-339432 |
0.441 |
|
| 2011 |
Dai Y, Grant S. Methods to study cancer therapeutic drugs that target cell cycle checkpoints. Methods in Molecular Biology (Clifton, N.J.). 782: 257-304. PMID 21870298 DOI: 10.1007/978-1-61779-273-1_19 |
0.419 |
|
| 2011 |
Grant S. Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors. Leukemia & Lymphoma. 52: 1623-5. PMID 21864041 DOI: 10.3109/10428194.2011.573890 |
0.582 |
|
| 2011 |
Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S, Cichy J, Shimoda K, Gamero A, Manjili M, Bear H, et al. The role of Tyk2 in regulation of breast cancer growth. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 31: 671-7. PMID 21864028 DOI: 10.1089/Jir.2011.0023 |
0.4 |
|
| 2011 |
Dai Y, Chen S, Wang L, Pei XY, Funk VL, Kramer LB, Dent P, Grant S. Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. The Journal of Biological Chemistry. 286: 34036-50. PMID 21816815 DOI: 10.1074/Jbc.M111.284216 |
0.463 |
|
| 2011 |
Bareford MD, Hamed HA, Tang Y, Cruickshanks N, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy. 7: 1261-2. PMID 21814046 DOI: 10.4161/Auto.7.10.17029 |
0.443 |
|
| 2011 |
Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 10: 1686-97. PMID 21750224 DOI: 10.1158/1535-7163.Mct-10-1108 |
0.558 |
|
| 2011 |
Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. Cancer Biology & Therapy. 12: 215-28. PMID 21642769 DOI: 10.4161/Cbt.12.3.16218 |
0.512 |
|
| 2011 |
Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research. 71: 4955-67. PMID 21622715 DOI: 10.1158/0008-5472.Can-11-0898 |
0.45 |
|
| 2011 |
Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America. 108: 8785-90. PMID 21555592 DOI: 10.1073/Pnas.1100769108 |
0.401 |
|
| 2011 |
Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Molecular Interventions. 11: 133-40. PMID 21540473 DOI: 10.1124/Mi.11.2.11 |
0.518 |
|
| 2011 |
Grant S. Enhancing proteotoxic stress as an anticancer strategy. Oncotarget. 2: 284-6. PMID 21525531 DOI: 10.18632/Oncotarget.268 |
0.308 |
|
| 2011 |
Pellicano F, Simara P, Sinclair A, Helgason GV, Copland M, Grant S, Holyoake TL. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia. 25: 1159-67. PMID 21483442 DOI: 10.1038/Leu.2011.67 |
0.507 |
|
| 2011 |
Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3219-32. PMID 21474579 DOI: 10.1158/1078-0432.Ccr-11-0234 |
0.54 |
|
| 2011 |
Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, ... ... Grant S, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3388-97. PMID 21447728 DOI: 10.1158/1078-0432.Ccr-10-2876 |
0.34 |
|
| 2011 |
Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. British Journal of Haematology. 153: 222-35. PMID 21375523 DOI: 10.1111/J.1365-2141.2011.08591.X |
0.51 |
|
| 2011 |
Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 117: 2807-12. PMID 21239695 DOI: 10.1182/Blood-2010-11-314708 |
0.335 |
|
| 2011 |
Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood. 117: 1947-57. PMID 21148814 DOI: 10.1182/Blood-2010-06-291146 |
0.538 |
|
| 2011 |
Park MA, Hamed HA, Mitchell C, Cruickshanks N, Dash R, Allegood J, Dmitriev IP, Tye G, Ogretmen B, Spiegel S, Yacoub A, Grant S, Curiel DT, Fisher PB, Dent P. A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels. Molecular Pharmacology. 79: 368-80. PMID 21119025 DOI: 10.1124/Mol.110.069484 |
0.416 |
|
| 2011 |
Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs. 29: 1004-12. PMID 20461440 DOI: 10.1007/S10637-010-9447-X |
0.336 |
|
| 2011 |
Holkova B, Bose P, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update Blood. 120: 3588-3588. DOI: 10.1182/Blood.V120.21.3588.3588 |
0.35 |
|
| 2011 |
Zingone A, Korde N, Chen J, Xi L, Raffeld M, Holkova B, Kmieciak M, Sullivan D, Doyle A, Maric I, Calvo K, Yancey MA, Mulquin M, Annunziata C, Grant S, et al. Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study Blood. 118: 306-306. DOI: 10.1182/Blood.V118.21.306.306 |
0.444 |
|
| 2011 |
Holkova B, Badros AZ, Geller R, Voorhees PM, Zingone A, Korde N, Lin H, Tombes MB, Shrader E, Sankala H, Kmieciak M, Roberts JD, Sullivan D, Landgren O, Grant S. A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma Blood. 118: 2931-2931. DOI: 10.1182/Blood.V118.21.2931.2931 |
0.354 |
|
| 2011 |
Bareford MD, Hamed HA, Park M, Grant S, Fisher P, Dent P. Abstract 5390: A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels Cancer Research. 71: 5390-5390. DOI: 10.1158/1538-7445.Am2011-5390 |
0.406 |
|
| 2011 |
Pei X, Dai Y, Youssefian LE, Chen S, Bodie W, Takabatake Y, Almenara G, Kramer L, Dent P, Grant S. Abstract 5367: Simultaneous inhibition of Chk1 and MEK1/2 targets non-proliferating multiple myeloma cells Cancer Research. 71: 5367-5367. DOI: 10.1158/1538-7445.Am2011-5367 |
0.35 |
|
| 2011 |
Dasmahapatra GP, Lembersky D, Friedberg JW, Fisher RI, Dent P, Grant S. Abstract 5366: The small molecule Bcl-2 antagonist obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC and ABC- sub types of DLBCL cells bothin vitroandin vivo Cancer Research. 71: 5366-5366. DOI: 10.1158/1538-7445.Am2011-5366 |
0.581 |
|
| 2011 |
Nguyen TK, Attkisson E, Dai Y, Kramer L, Muschen M, Grant S. Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cellsin vitroandin vivo Cancer Research. 71: 2572-2572. DOI: 10.1158/1538-7445.Am2011-2572 |
0.533 |
|
| 2010 |
Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, Yacoub A, Rahmani M, Emdad L, Dmitriev IP, Wang XY, ... ... Grant S, et al. mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine & Growth Factor Reviews. 21: 381-91. PMID 20926331 DOI: 10.1016/J.Cytogfr.2010.08.004 |
0.382 |
|
| 2010 |
Rahmani M, Mayo M, Dash R, Sokhi UK, Dmitriev IP, Sarkar D, Dent P, Curiel DT, Fisher PB, Grant S. Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress. Molecular Pharmacology. 78: 1096-104. PMID 20858700 DOI: 10.1124/Mol.110.068007 |
0.42 |
|
| 2010 |
Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology. 151: 70-83. PMID 20701602 DOI: 10.1111/J.1365-2141.2010.08319.X |
0.586 |
|
| 2010 |
Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, Richards KL, Hammond SM, Graves LM. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Molecular Pharmacology. 78: 811-7. PMID 20693279 DOI: 10.1124/Mol.110.066258 |
0.402 |
|
| 2010 |
Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Molecular Cancer Therapeutics. 9: 2220-31. PMID 20682655 DOI: 10.1158/1535-7163.Mct-10-0274 |
0.356 |
|
| 2010 |
Grant S. HDAC inhibitors repress the polycomb protein BMI1. Cell Cycle (Georgetown, Tex.). 9: 2705-6. PMID 20676031 DOI: 10.4161/Cc.9.14.12324 |
0.45 |
|
| 2010 |
Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Research. 70: 6313-24. PMID 20631069 DOI: 10.1158/0008-5472.Can-10-0999 |
0.412 |
|
| 2010 |
Li Q, Wu J, Zheng H, Liu K, Guo TL, Liu Y, Eblen ST, Grant S, Zhang S. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. Bioorganic & Medicinal Chemistry Letters. 20: 4526-30. PMID 20580230 DOI: 10.1016/J.Bmcl.2010.06.030 |
0.478 |
|
| 2010 |
Dash R, Richards JE, Su ZZ, Bhutia SK, Azab B, Rahmani M, Dasmahapatra G, Yacoub A, Dent P, Dmitriev IP, Curiel DT, Grant S, Pellecchia M, Reed JC, Sarkar D, et al. Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Research. 70: 5034-45. PMID 20501829 DOI: 10.1158/0008-5472.Can-10-0563 |
0.386 |
|
| 2010 |
Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Häussinger D, Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Molecular Cancer Therapeutics. 9: 1378-95. PMID 20442308 DOI: 10.1158/1535-7163.Mct-09-1131 |
0.48 |
|
| 2010 |
Bhutia SK, Dash R, Das SK, Azab B, Su ZZ, Lee SG, Grant S, Yacoub A, Dent P, Curiel DT, Sarkar D, Fisher PB. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Research. 70: 3667-76. PMID 20406981 DOI: 10.1158/0008-5472.Can-09-3647 |
0.432 |
|
| 2010 |
Dai Y, Grant S. Targeting Chk1 in the replicative stress response. Cell Cycle (Georgetown, Tex.). 9: 1025. PMID 20237419 DOI: 10.4161/Cc.9.6.11155 |
0.427 |
|
| 2010 |
Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 115: 4478-87. PMID 20233973 DOI: 10.1182/Blood-2009-12-257261 |
0.581 |
|
| 2010 |
Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1130-42. PMID 20179672 DOI: 10.1038/Mt.2010.29 |
0.446 |
|
| 2010 |
Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leukemia Research. 34: 379-86. PMID 20117835 DOI: 10.1016/J.Leukres.2009.07.013 |
0.545 |
|
| 2010 |
Hamed HA, Yacoub A, Park MA, Eulitt P, Sarkar D, Dimitrie IP, Chen CS, Grant S, Curiel DT, Fisher PB, Dent P. OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biology & Therapy. 9: 526-36. PMID 20107314 DOI: 10.4161/Cbt.9.7.11116 |
0.481 |
|
| 2010 |
Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, Grant S, Curiel DT, Fisher PB, Dent P. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Research. 70: 1120-9. PMID 20103619 DOI: 10.1158/0008-5472.Can-09-4043 |
0.483 |
|
| 2010 |
Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry. 285: 10064-77. PMID 20065354 DOI: 10.1074/Jbc.M109.095208 |
0.449 |
|
| 2010 |
Fathi AT, Grant S, Karp JE. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treatment Reviews. 36: 142-50. PMID 20056334 DOI: 10.1016/J.Ctrv.2009.12.004 |
0.434 |
|
| 2010 |
Grant S. New agents for AML and MDS. Best Practice & Research. Clinical Haematology. 22: 501-7. PMID 19959100 DOI: 10.1016/J.Beha.2009.08.003 |
0.361 |
|
| 2010 |
Yacoub A, Liu R, Park MA, Hamed HA, Dash R, Schramm DN, Sarkar D, Dimitriev IP, Bell JK, Grant S, Farrell NP, Curiel DT, Fisher PB, Dent P. Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Molecular Pharmacology. 77: 298-310. PMID 19910452 DOI: 10.1124/Mol.109.061820 |
0.435 |
|
| 2010 |
Dasmahapatra G, Lembersky D, Friedberg JW, Fisher RI, Dent P, Grant S. Histone Deacetylase Inhibitors Potentiate the Lethality of the Irreversible Proteasome Inhibitor Carfilzomib In Mantle Cell Lymphoma Cells In Vitro and In Vivo Blood. 116: 3938-3938. DOI: 10.1182/Blood.V116.21.3938.3938 |
0.603 |
|
| 2010 |
Dai Y, Chen S, Wang L, Pei X, Kramer L, Dent P, Grant S. Bortezomib Interacts Synergistically with Belinostat to Induce Apoptosis In Human Acute Myeloid and Lymphoid Leukemia Cells Blood. 116: 3266-3266. DOI: 10.1182/Blood.V116.21.3266.3266 |
0.551 |
|
| 2010 |
Dai Y, Chen S, Wang L, Myers J, Thompson N, Pei X, Orlowski R, Dent P, Grant S. Abstract 667: Mechanisms underlying synergistic interactions between the CDK inhibitor flavopiridol (Alvocidib) and the BH3 mimetic GX15-070 (Obatoclax) in human multiple myeloma cells Cancer Research. 70: 667-667. DOI: 10.1158/1538-7445.Am10-667 |
0.567 |
|
| 2010 |
Nguyen TK, Kolla S, Dai Y, Grant S. Abstract 5412: Synergistic interactions between histone deacetylase inhibitors and aurora kinase inhibitor KW2449 Ph+ cells Cancer Research. 70: 5412-5412. DOI: 10.1158/1538-7445.Am10-5412 |
0.541 |
|
| 2010 |
Rahmani M, Mayo M, Dent P, Grant S. Abstract 4523: Inhibition of Bcl-2 antiapoptotic members by obatoclax dramatically potentiates sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process Cancer Research. 70: 4523-4523. DOI: 10.1158/1538-7445.Am10-4523 |
0.511 |
|
| 2010 |
Rahmani M, Mayo M, Dash R, Dent P, Fisher PB, Grant S. Abstract 1511: mda-7/IL-24 potently induces apoptosis in human leukemia cells through a process involving induction of ER stress Cancer Research. 70: 1511-1511. DOI: 10.1158/1538-7445.Am10-1511 |
0.435 |
|
| 2010 |
Bhutia SK, Dash R, Azab B, Das S, Su Z, Lee S, Grant S, Dent P, Curiel DT, Sarkar D, Fisher PB. Abstract 1038: Defining the mechanism by which melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24)-induced autophagy switches to apoptosis in prostate cancer cells Cancer Research. 70: 1038-1038. DOI: 10.1158/1538-7445.Am10-1038 |
0.426 |
|
| 2009 |
Dent P, Curiel DT, Grant S, Fisher PB. Minting a new class of polo-like-kinase inhibitors. Cancer Biology & Therapy. 8: 2384-5. PMID 20009506 DOI: 10.4161/Cbt.8.24.10389 |
0.349 |
|
| 2009 |
Grant S. Targeting histone demethylases in cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7111-3. PMID 19934292 DOI: 10.1158/1078-0432.Ccr-09-2399 |
0.361 |
|
| 2009 |
Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biology & Therapy. 8: 2084-96. PMID 19823038 DOI: 10.4161/Cbt.8.21.9895 |
0.567 |
|
| 2009 |
Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Molecular and Cellular Biology. 29: 6149-69. PMID 19805519 DOI: 10.1128/Mcb.01481-08 |
0.499 |
|
| 2009 |
Li Q, Al-Ayoubi A, Guo T, Zheng H, Sarkar A, Nguyen T, Eblen ST, Grant S, Kellogg GE, Zhang S. Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 6042-6. PMID 19796943 DOI: 10.1016/J.Bmcl.2009.09.057 |
0.481 |
|
| 2009 |
Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood. 114: 4507-16. PMID 19773546 DOI: 10.1182/Blood-2008-09-177881 |
0.541 |
|
| 2009 |
Grant S. Selectively killing transformed cells through proteasome inhibition. Cell Cycle (Georgetown, Tex.). 8: 3074-5. PMID 19770579 DOI: 10.4161/Cc.8.19.9815 |
0.513 |
|
| 2009 |
Leonard JP, Williams ME, Goy A, Grant S, Pfreundschuh M, Rosen ST, Sweetenham JW. Mantle cell lymphoma: biological insights and treatment advances. Clinical Lymphoma & Myeloma. 9: 267-77. PMID 19717376 DOI: 10.3816/Clm.2009.N.055 |
0.374 |
|
| 2009 |
Grant S. CDK inhibitors and immune responses. Cell Cycle (Georgetown, Tex.). 8: 2484. PMID 19684461 DOI: 10.4161/Cc.8.16.9346 |
0.42 |
|
| 2009 |
Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clinical Cancer Research. 15: 5250-5257. PMID 19671864 DOI: 10.1158/1078-0432.Ccr-08-2850 |
0.324 |
|
| 2009 |
Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Molecular Pharmacology. 76: 327-41. PMID 19483105 DOI: 10.1124/Mol.109.056309 |
0.497 |
|
| 2009 |
Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, Houghton PJ, Voelkel-Johnson C, Grant S, Dent P. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Molecular Pharmacology. 76: 342-55. PMID 19483104 DOI: 10.1124/Mol.109.056523 |
0.361 |
|
| 2009 |
Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, Koumenis C, Spiegel S, Curiel DT, Voelkel-Johnson C, Grant S, et al. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Molecular Cancer Therapeutics. 8: 1280-91. PMID 19417161 DOI: 10.1158/1535-7163.Mct-09-0073 |
0.497 |
|
| 2009 |
Rambal AA, Panaguiton ZL, Kramer L, Grant S, Harada H. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia. 23: 1744-54. PMID 19404317 DOI: 10.1038/Leu.2009.80 |
0.531 |
|
| 2009 |
Dent P, Curiel DT, Fisher PB, Grant S. Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 65-73. PMID 19395305 DOI: 10.1016/J.Drup.2009.03.001 |
0.454 |
|
| 2009 |
Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, Grant S, Dent P, Curiel DT, Sarkar D, Fisher PB. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biology & Therapy. 8: 391-400. PMID 19276652 DOI: 10.4161/Cbt.8.5.7581 |
0.33 |
|
| 2009 |
Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biology & Therapy. 8: 808-19. PMID 19270531 DOI: 10.4161/Cbt.8.9.8131 |
0.493 |
|
| 2009 |
Dent P, Grant S, Fisher PB, Curiel DT. PI3K: A rational target for ovarian cancer therapy? Cancer Biology & Therapy. 8: 27-30. PMID 19127116 DOI: 10.4161/Cbt.8.1.7365 |
0.353 |
|
| 2009 |
Dai Y, Chen S, Pei X, Ramakrishnan V, Wang M, Orlowski R, Dent P, Grant S. Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism. Blood. 114: 297-297. DOI: 10.1182/Blood.V114.22.297.297 |
0.559 |
|
| 2009 |
Dasmahapatra G, Lembersky D, Kramer L, Friedberg JW, Fisher RI, Dent P, Grant S. The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF-κB Inactivation, and DNA Damage.. Blood. 114: 1688-1688. DOI: 10.1182/Blood.V114.22.1688.1688 |
0.597 |
|
| 2008 |
Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN, Chandrupatla HR, Hansen M, Ajmal S, Papanicolaou GJ, Guo Y, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. Plos One. 3: e3583. PMID 18974833 DOI: 10.1371/Journal.Pone.0003583 |
0.345 |
|
| 2008 |
Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, Grant S. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions Molecular Cancer Therapeutics. 7: 3285-3297. PMID 18852132 DOI: 10.1158/1535-7163.Mct-08-0385 |
0.416 |
|
| 2008 |
Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, Dent P. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Molecular Cancer Therapeutics. 7: 2633-48. PMID 18790746 DOI: 10.1158/1535-7163.Mct-08-0400 |
0.559 |
|
| 2008 |
Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, Spiegel S, Norris J, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biology & Therapy. 7: 1648-62. PMID 18787411 DOI: 10.4161/Cbt.7.10.6623 |
0.401 |
|
| 2008 |
Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5385-99. PMID 18765530 DOI: 10.1158/1078-0432.Ccr-08-0469 |
0.424 |
|
| 2008 |
Park MA, Zhang G, Norris J, Hylemon PB, Fisher PB, Grant S, Dent P. Regulation of autophagy by ceramide-CD95-PERK signaling Autophagy. 4: 929-931. PMID 18719356 DOI: 10.4161/Auto.6732 |
0.488 |
|
| 2008 |
Dent P, Yacoub A, Park M, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB. Searching for a cure: gene therapy for glioblastoma. Cancer Biology & Therapy. 7: 1335-40. PMID 18708757 DOI: 10.4161/Cbt.7.9.6408 |
0.459 |
|
| 2008 |
Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, Dent P, Grant S. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood. 112: 2439-49. PMID 18614762 DOI: 10.1182/Blood-2008-05-159392 |
0.473 |
|
| 2008 |
Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 283: 24343-58. PMID 18614532 DOI: 10.1074/Jbc.M803444200 |
0.503 |
|
| 2008 |
Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, Grant S, Dent P. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Molecular Pharmacology. 74: 807-22. PMID 18544666 DOI: 10.1124/Mol.108.047365 |
0.538 |
|
| 2008 |
Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S, Spiegel S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 112: 1382-91. PMID 18511810 DOI: 10.1182/Blood-2008-02-138958 |
0.553 |
|
| 2008 |
Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, Grant S. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood. 112: 793-804. PMID 18505786 DOI: 10.1182/Blood-2007-10-116376 |
0.525 |
|
| 2008 |
Hamed H, Mitchell C, Park MA, Hanna D, Martin AP, Harrison B, Hawkins W, Curiel DA, Fisher PB, Grant S, Yacoub A, Hagan MP, Dent P. Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. Cancer Biology & Therapy. 7: 587-93. PMID 18379195 DOI: 10.4161/Cbt.7.4.5543 |
0.436 |
|
| 2008 |
Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus WC, Ramakrishnan V, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB, Dent P. MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biology & Therapy. 7: 917-33. PMID 18376144 DOI: 10.4161/Cbt.7.6.5928 |
0.397 |
|
| 2008 |
Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Molecular Cancer Therapeutics. 7: 616-29. PMID 18347148 DOI: 10.1158/1535-7163.Mct-07-2376 |
0.426 |
|
| 2008 |
Park MA, Yacoub A, Sarkar D, Emdad L, Rahmani M, Spiegel S, Koumenis C, Graf M, Curiel DT, Grant S, Fisher PB, Dent P. PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy. 4: 513-5. PMID 18299661 DOI: 10.4161/Auto.5725 |
0.562 |
|
| 2008 |
Yacoub A, Gupta P, Park MA, Rhamani M, Hamed H, Hanna D, Zhang G, Sarkar D, Lebedeva IV, Emdad L, Koumenis C, Curiel DT, Grant S, Fisher PB, Dent P. Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling Molecular Cancer Therapeutics. 7: 314-329. PMID 18281516 DOI: 10.1158/1535-7163.Mct-07-2150 |
0.541 |
|
| 2008 |
Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, Hanna D, Sarkar D, Lebedeva IV, Emdad L, Sauane M, Vozhilla N, Spiegel S, Koumenis C, Graf M, ... ... Grant S, et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Molecular Cancer Therapeutics. 7: 297-313. PMID 18281515 DOI: 10.1158/1535-7163.Mct-07-2166 |
0.561 |
|
| 2008 |
Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 549-58. PMID 18223231 DOI: 10.1158/1078-0432.Ccr-07-1934 |
0.408 |
|
| 2008 |
Park MA, Curiel DT, Koumenis C, Graf M, Chen CS, Fisher PB, Grant S, Dent P. PERK-dependent regulation of HSP70 expression and the regulation of autophagy. Autophagy. 4: 364-7. PMID 18216498 DOI: 10.4161/Auto.5593 |
0.479 |
|
| 2008 |
Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, Calderwood SK, Sherman MY, Koumenis C, Spiegel S, Chen CS, Graf M, Curiel DT, Fisher PB, Grant S, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Molecular Pharmacology. 73: 1168-84. PMID 18182481 DOI: 10.1124/Mol.107.042697 |
0.505 |
|
| 2008 |
Grant S, Kolla S, Sirulnik LA, Shapiro G, Supko J, Cooper B, Perkins E, Ramakrishnan V, Espinoza-Delgado I, Tombes MB, Roberts JD. Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2) Blood. 112: 2986-2986. DOI: 10.1182/Blood.V112.11.2986.2986 |
0.318 |
|
| 2007 |
Dent P, Hylemon PB, Grant S, Fisher PB. Approaches for monitoring signal transduction changes in normal and cancer cells Methods in Molecular Biology (Clifton, N.J.). 383: 259-276. PMID 18217691 DOI: 10.1007/978-1-59745-335-6_17 |
0.363 |
|
| 2007 |
Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, Roberts JD, Grant S, Dent P. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Molecular Cancer Therapeutics. 6: 3101-12. PMID 18065490 DOI: 10.1158/1535-7163.Mct-07-0561 |
0.58 |
|
| 2007 |
Colo GP, Rosato RR, Grant S, Costas MA. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. Febs Letters. 581: 5075-81. PMID 17927986 DOI: 10.1016/J.Febslet.2007.09.052 |
0.495 |
|
| 2007 |
Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, Park ES, ... ... Grant S, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). International Journal of Oncology. 31: 985-1007. PMID 17912425 DOI: 10.3892/Ijo.31.5.985 |
0.369 |
|
| 2007 |
Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Research. 67: 9490-500. PMID 17909059 DOI: 10.1158/0008-5472.Can-07-0598 |
0.549 |
|
| 2007 |
Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation Clinical Cancer Research. 13: 4280-4290. PMID 17634558 DOI: 10.1158/1078-0432.Ccr-07-0835 |
0.566 |
|
| 2007 |
Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Molecular Pharmacology. 72: 788-95. PMID 17595328 DOI: 10.1124/Mol.106.033308 |
0.576 |
|
| 2007 |
Grant S, Dent P. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: Implications for new approaches to the treatment of childhood leukemias Current Drug Targets. 8: 751-759. PMID 17584030 DOI: 10.2174/138945007780830764 |
0.49 |
|
| 2007 |
Mitchell C, Kabolizadeh P, Ryan J, Roberts JD, Yacoub A, Curiel DT, Fisher PB, Hagan MP, Farrell NP, Grant S, Dent P. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Molecular Pharmacology. 72: 704-14. PMID 17578896 DOI: 10.1124/Mol.107.038406 |
0.577 |
|
| 2007 |
Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Molecular and Cellular Biology. 27: 5499-513. PMID 17548474 DOI: 10.1128/Mcb.01080-06 |
0.55 |
|
| 2007 |
Pei XY, Dai Y, Tenorio S, Lu J, Harada H, Dent P, Grant S. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood. 110: 2092-101. PMID 17540843 DOI: 10.1182/Blood-2007-04-083204 |
0.587 |
|
| 2007 |
Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Research. 67: 2908-11. PMID 17409392 DOI: 10.1158/0008-5472.can-07-0082 |
0.33 |
|
| 2007 |
Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P. Radiation-induced cell signaling: inside-out and outside-in. Molecular Cancer Therapeutics. 6: 789-801. PMID 17363476 DOI: 10.1158/1535-7163.Mct-06-0596 |
0.486 |
|
| 2007 |
Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Giménez MS, Dent P, Grant S. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions Molecular Cancer Therapeutics. 6: 692-702. PMID 17308065 DOI: 10.1158/1535-7163.Mct-06-0562 |
0.437 |
|
| 2007 |
Mitchell C, Park MA, Zhang G, Han SI, Harada H, Franklin RA, Yacoub A, Li PL, Hylemon PB, Grant S, Dent P. 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. Molecular Cancer Therapeutics. 6: 618-32. PMID 17308059 DOI: 10.1158/1535-7163.Mct-06-0532 |
0.55 |
|
| 2007 |
Dai Y, Khanna P, Chen S, Pei XY, Dent P, Grant S. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood. 109: 4415-23. PMID 17264303 DOI: 10.1182/Blood-2006-09-047076 |
0.506 |
|
| 2007 |
Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Research. 67: 782-91. PMID 17234790 DOI: 10.1158/0008-5472.Can-06-3964 |
0.555 |
|
| 2007 |
Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood. 109: 4006-15. PMID 17218385 DOI: 10.1182/Blood-2006-09-045039 |
0.531 |
|
| 2007 |
Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, Su ZZ, Grant S, Dent P, Curiel DT, Senzer N, Nemunaitis J. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicology and Applied Pharmacology. 224: 300-7. PMID 17208263 DOI: 10.1016/J.Taap.2006.11.021 |
0.387 |
|
| 2007 |
Fang Y, Studer E, Mitchell C, Grant S, Pandak WM, Hylemon PB, Dent P. Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling. Molecular Pharmacology. 71: 1122-8. PMID 17200418 DOI: 10.1124/Mol.106.032060 |
0.358 |
|
| 2007 |
Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. Molecular Pharmacology. 71: 259-75. PMID 17050804 DOI: 10.1124/Mol.106.031153 |
0.543 |
|
| 2007 |
Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opinion On Therapeutic Targets. 9: 809-24. PMID 16083344 DOI: 10.1517/14728222.9.4.809 |
0.362 |
|
| 2006 |
Yacoub A, Miller A, Caron RW, Qiao L, Curiel DA, Fisher PB, Hagan MP, Grant S, Dent P. Radiotherapy-induced signal transduction. Endocrine-Related Cancer. 13: S99-114. PMID 17259563 DOI: 10.1677/Erc.1.01271 |
0.441 |
|
| 2006 |
Rébé C, Cathelin S, Launay S, Filomenko R, Prévotat L, L'Ollivier C, Gyan E, Micheau O, Grant S, Dubart-Kupperschmitt A, Fontenay M, Solary E. Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. Blood. 109: 1442-50. PMID 17047155 DOI: 10.1182/blood-2006-03-011585 |
0.315 |
|
| 2006 |
Yacoub A, Gilfor D, Hawkins W, Park MA, Hanna D, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P. MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. Cancer Biology & Therapy. 5: 1332-9. PMID 16957420 DOI: 10.4161/Cbt.5.10.3215 |
0.38 |
|
| 2006 |
Pei XY, Li W, Dai Y, Dent P, Grant S. Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells. Molecular Pharmacology. 70: 1965-73. PMID 16940414 DOI: 10.1124/Mol.106.028373 |
0.505 |
|
| 2006 |
Jia W, Hegde VL, Singh NP, Sisco D, Grant S, Nagarkatti M, Nagarkatti PS. Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Molecular Cancer Research : McR. 4: 549-62. PMID 16908594 DOI: 10.1158/1541-7786.Mcr-05-0193 |
0.528 |
|
| 2006 |
Gao N, Kramer L, Rahmani M, Dent P, Grant S. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Molecular Pharmacology. 70: 645-55. PMID 16672643 DOI: 10.1124/Mol.106.024505 |
0.528 |
|
| 2006 |
Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Molecular Pharmacology. 70: 589-603. PMID 16622074 DOI: 10.1124/Mol.106.025007 |
0.57 |
|
| 2006 |
Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2239-47. PMID 16609040 DOI: 10.1158/1078-0432.Ccr-05-2282 |
0.44 |
|
| 2006 |
Dai Y, Grant S. CDK inhibitor targets: a hit or miss proposition?: cyclin-dependent kinase inhibitors kill tumor cells by downregulation of anti-apoptotic proteins. Cancer Biology & Therapy. 5: 171-3. PMID 16552171 DOI: 10.4161/Cbt.5.2.2568 |
0.501 |
|
| 2006 |
Dasmahapatra G, Nguyen TK, Dent P, Grant S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leukemia Research. 30: 1263-72. PMID 16481037 DOI: 10.1016/J.Leukres.2006.01.005 |
0.478 |
|
| 2006 |
Dai Y, Hamm TE, Dent P, Grant S. Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry Cell Cycle. 5: 437-446. PMID 16479154 DOI: 10.4161/Cc.5.4.2441 |
0.474 |
|
| 2006 |
Bartimole TM, Vrana JA, Freemerman AJ, Jarvis WD, Reed JC, Boise LH, Grant S. Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis. Cell Death and Differentiation. 4: 294-303. PMID 16465244 DOI: 10.1038/Sj.Cdd.4400242 |
0.443 |
|
| 2006 |
Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, Bachelor MA, Grant S, Curiel DT, Dent P, Fisher PB. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacology & Therapeutics. 111: 596-628. PMID 16464504 DOI: 10.1016/J.Pharmthera.2005.11.005 |
0.397 |
|
| 2006 |
Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P, Grant S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Molecular Pharmacology. 69: 216-25. PMID 16189296 DOI: 10.1124/Mol.105.017145 |
0.521 |
|
| 2006 |
Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism Blood. 107: 232-240. PMID 16166589 DOI: 10.1182/Blood-2005-06-2302 |
0.524 |
|
| 2005 |
Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biology & Therapy. 4: 1275-84. PMID 16319524 DOI: 10.4161/Cbt.4.11.2286 |
0.376 |
|
| 2005 |
Rosato RR, Almenara JA, Maggio SC, Atadja P, Craig R, Vrana J, Dent P, Grant S. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells Molecular Cancer Therapeutics. 4: 1772-1785. PMID 16275999 DOI: 10.1158/1535-7163.Mct-05-0157 |
0.496 |
|
| 2005 |
Dasmahapatra G, Almenara JA, Grant S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Molecular Pharmacology. 69: 288-98. PMID 16219908 DOI: 10.1124/mol.105.016154 |
0.468 |
|
| 2005 |
Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochemical Pharmacology. 70: 1685-96. PMID 16207485 DOI: 10.1016/J.Bcp.2005.08.020 |
0.322 |
|
| 2005 |
Gao N, Rahmani M, Shi X, Dent P, Grant S. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. Blood. 107: 241-9. PMID 16141349 DOI: 10.1182/Blood-2005-06-2409 |
0.52 |
|
| 2005 |
Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation Journal of Biological Chemistry. 280: 35217-35227. PMID 16109713 DOI: 10.1074/Jbc.M506551200 |
0.582 |
|
| 2005 |
Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells Leukemia. 19: 1579-1589. PMID 16015388 DOI: 10.1038/Sj.Leu.2403868 |
0.537 |
|
| 2005 |
Dent P, Yacoub A, Grant S. DMC: Novel celecoxib derivatives to rap cancer Cancer Biology and Therapy. 4: 583-584. PMID 15970676 DOI: 10.4161/Cbt.4.5.1794 |
0.306 |
|
| 2005 |
Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation Molecular and Cellular Biology. 25: 5429-5444. PMID 15964800 DOI: 10.1128/Mcb.25.13.5429-5444.2005 |
0.483 |
|
| 2005 |
Pei XY, Dai Y, Rahmani M, Li W, Dent P, Grant S. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4589-600. PMID 15958645 DOI: 10.1158/1078-0432.Ccr-04-2346 |
0.463 |
|
| 2005 |
Dent P, Yacoub A, Grant S, Curiel DT, Fisher PB. MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: A new cancer therapy? Journal of Cellular Biochemistry. 95: 712-719. PMID 15880678 DOI: 10.1002/Jcb.20502 |
0.356 |
|
| 2005 |
Louis M, Rosato RR, Battaglia E, Néguesque A, Lapotre A, Grant S, Bagrel D. Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells. International Journal of Oncology. 26: 1569-74. PMID 15870871 |
0.34 |
|
| 2005 |
Gao N, Rahmani M, Dent P, Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process Oncogene. 24: 3797-3809. PMID 15782127 DOI: 10.1038/Sj.Onc.1208530 |
0.424 |
|
| 2005 |
Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Research. 65: 2422-32. PMID 15781658 DOI: 10.1158/0008-5472.Can-04-2440 |
0.583 |
|
| 2005 |
Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Molecular Cancer Therapeutics. 4: 457-70. PMID 15767555 DOI: 10.1158/1535-7163.Mct-04-0137 |
0.569 |
|
| 2005 |
Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, Dennis PA, Hagan MP, Grant S, Dent P. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Molecular Cancer Therapeutics. 4: 257-70. PMID 15713897 |
0.317 |
|
| 2005 |
Carón RW, Yacoub A, Mitchell C, Zhu X, Hong Y, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P. Radiation-stimulated ERK1/2 and JNK1/2 signaling can promote cell cycle progression in human colon cancer cells. Cell Cycle (Georgetown, Tex.). 4: 456-64. PMID 15655348 DOI: 10.4161/Cc.4.3.1249 |
0.404 |
|
| 2005 |
Pei XY, Dai Y, Grant S. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Molecular Cancer Therapeutics. 3: 1513-24. PMID 15634644 |
0.457 |
|
| 2005 |
Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Molecular Pharmacology. 67: 1166-76. PMID 15625278 DOI: 10.1124/Mol.104.007831 |
0.563 |
|
| 2005 |
Bouton LA, Ramirez CD, Bailey DP, Yeatman CF, Yue J, Wright HV, Domen J, Rosato RR, Grant S, Fischer-Stenger K, Ryan JJ. Costimulation with interleukin-4 and interleukin-10 induces mast cell apoptosis and cell-cycle arrest: the role of p53 and the mitochondrion. Experimental Hematology. 32: 1137-45. PMID 15588938 DOI: 10.1016/J.Exphem.2004.09.002 |
0.38 |
|
| 2005 |
Louis M, Rosato RR, Brault L, Osbild S, Battaglia E, Yang XH, Grant S, Bagrel D. The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. International Journal of Oncology. 25: 1701-11. PMID 15547708 |
0.457 |
|
| 2005 |
Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P, Grant S. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood. 105: 1706-16. PMID 15494423 DOI: 10.1182/Blood-2004-07-2767 |
0.455 |
|
| 2005 |
Grant S, Sullivan D, Roodman D, Stuart R, Perkins EB, Ramakrishnan V, Wright J, Colevas AD, Roberts JD. Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms. Blood. 106: 3338-3338. DOI: 10.1182/Blood.V106.11.3338.3338 |
0.38 |
|
| 2005 |
Grant S, Karp JE, Koc ON, Cooper B, Luger S, Figg WD, Egorin M, Druker BJ, Jacobberger JW, Ramakrishnan V, Perkins EB, Colevas AD, Roberts JD. Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies. Blood. 106: 1102-1102. DOI: 10.1182/Blood.V106.11.1102.1102 |
0.409 |
|
| 2004 |
Dent P, Grant S. Irofulven: Resurgence for alkylating therapy in cancer? Cancer Biology and Therapy. 3: 1143-1144. PMID 15640616 DOI: 10.4161/Cbt.3.11.1306 |
0.364 |
|
| 2004 |
Grant S. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia? Leukemia. 18: 1931-3. PMID 15496978 DOI: 10.1038/Sj.Leu.2403522 |
0.359 |
|
| 2004 |
Ahmed W, Rahmani M, Dent P, Grant S. The cyclin-dependent kinase inhibitor p21CIP1/WAF1 blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells Cell Cycle. 3: 1305-1311. PMID 15467449 DOI: 10.4161/Cc.3.10.1161 |
0.823 |
|
| 2004 |
Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant ST. Potent antileukemia interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation Leukemia. 18: 1780-1788. PMID 15385934 DOI: 10.1038/sj.leu.2403491 |
0.465 |
|
| 2004 |
Fang Y, Han SI, Mitchell C, Gupta S, Studer E, Grant S, Hylemon PB, Dent P. Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology (Baltimore, Md.). 40: 961-71. PMID 15382121 DOI: 10.1002/hep.20385 |
0.404 |
|
| 2004 |
Gao N, Dai Y, Rahmani M, Dent P, Grant S. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Molecular Pharmacology. 66: 956-63. PMID 15235103 DOI: 10.1124/Mol.104.002014 |
0.518 |
|
| 2004 |
Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, Sauane M, Lebedeva IV, Curiel DT, Mahasreshti PJ, Rosenfeld MR, Broaddus WC, James CD, Grant S, Fisher PB, et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biology & Therapy. 3: 739-51. PMID 15197348 DOI: 10.4161/Cbt.3.8.968 |
0.571 |
|
| 2004 |
Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. The Journal of Biological Chemistry. 279: 34227-39. PMID 15175350 DOI: 10.1074/Jbc.M402290200 |
0.547 |
|
| 2004 |
Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3839-52. PMID 15173093 DOI: 10.1158/1078-0432.Ccr-03-0561 |
0.46 |
|
| 2004 |
Grant S, Dent P. Activation of MAP kinase pathways by TRAIL: Don't expect the obvious Cancer Biology and Therapy. 3: 302-304. PMID 15107606 DOI: 10.4161/Cbt.3.3.749 |
0.438 |
|
| 2004 |
Yu C, Rahmani M, Dent P, Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib Experimental Cell Research. 295: 555-566. PMID 15093752 DOI: 10.1016/J.Yexcr.2004.02.001 |
0.477 |
|
| 2004 |
Grant S, Dent P. Kinase Inhibitors and Cytotoxic Drug Resistance Clinical Cancer Research. 10: 2205-2207. PMID 15073093 DOI: 10.1158/1078-0432.Ccr-0001-4 |
0.401 |
|
| 2004 |
Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Research. 64: 2590-600. PMID 15059916 DOI: 10.1158/0008-5472.Can-03-2631 |
0.519 |
|
| 2004 |
Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood. 104: 509-18. PMID 15039284 DOI: 10.1182/Blood-2003-12-4121 |
0.487 |
|
| 2004 |
Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Molecular Pharmacology. 65: 571-81. PMID 14978235 DOI: 10.1124/mol.65.3.571 |
0.404 |
|
| 2004 |
Han SI, Studer E, Gupta S, Fang Y, Qiao L, Li W, Grant S, Hylemon PB, Dent P. Bile Acids Enhance the Activity of the Insulin Receptor and Glycogen Synthase in Primary Rodent Hepatocytes Hepatology. 39: 456-463. PMID 14767998 DOI: 10.1002/Hep.20043 |
0.33 |
|
| 2004 |
Harada H, Grant S. Apoptosis regulators. Reviews in Clinical and Experimental Hematology. 7: 117-38. PMID 14763159 |
0.38 |
|
| 2004 |
Dai Y, Grant S. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Current Oncology Reports. 6: 123-30. PMID 14751090 DOI: 10.1007/s11912-004-0024-3 |
0.434 |
|
| 2004 |
Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Molecular Cancer Therapeutics. 2: 1273-84. PMID 14707268 |
0.459 |
|
| 2004 |
Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, Dent P. Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biology & Therapy. 2: 670-6. PMID 14688474 |
0.484 |
|
| 2004 |
Rosato RR, Grant S. Histone deacetylase inhibitors in clinical development. Expert Opinion On Investigational Drugs. 13: 21-38. PMID 14680450 DOI: 10.1517/13543784.13.1.21 |
0.328 |
|
| 2004 |
Yu C, Rahmani M, Almenara J, Sausville EA, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process Oncogene. 23: 1364-1376. PMID 14647418 DOI: 10.1038/Sj.Onc.1207248 |
0.406 |
|
| 2004 |
Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P, Grant S. Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood. 103: 2761-70. PMID 14645003 DOI: 10.1182/Blood-2003-09-3037 |
0.471 |
|
| 2004 |
Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Current Opinion in Pharmacology. 3: 362-70. PMID 12901944 DOI: 10.1016/s1471-4892(03)00079-1 |
0.453 |
|
| 2004 |
Dai Y, Rahmani M, Pei X, Khanna P, Dent P, Grant S. Highly Synergistic Interaction between Farnesyltransferase Inhibitors and the Chk1 Inhibitor UCN-01 to Induce Apoptosis in Human Leukemia Cells through Interruption of Both Akt and MEK/ERK Pathways and Activation of SEK1/JNK. Blood. 104: 3403-3403. DOI: 10.1182/Blood.V104.11.3403.3403 |
0.454 |
|
| 2004 |
Rahmani M, Reese E, Dai Y, Bauer C, Kramer L, Huang M, Jove R, Dent P, Grant S. Co-Administration of SAHA and 17-AAG Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI-571 in Association with Down-Regulation of Bcr-Abl, Abrogation of STAT5 Activity, and Bax Conformational Change. Blood. 104: 1995-1995. DOI: 10.1182/Blood.V104.11.1995.1995 |
0.544 |
|
| 2004 |
Fang Y, Han SI, Mitchell C, Gupta S, Studer E, Grant S, Hylemon PB, Dent P. Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes Hepatology. 40: 961-971. DOI: 10.1002/Hep.1840400427 |
0.501 |
|
| 2003 |
Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Research. 63: 8420-7. PMID 14679005 |
0.762 |
|
| 2003 |
Dai Y, Dent P, Grant S. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Mitochondrial Dysfunction and Apoptosis Induced by 7-Hydroxystaurosporine and Mitogen-Activated Protein Kinase Kinase Inhibitors in Human Leukemia Cells That Ectopically Express Bcl-2 and Bcl-xL Molecular Pharmacology. 64: 1402-1409. PMID 14645670 DOI: 10.1124/Mol.64.6.1402 |
0.554 |
|
| 2003 |
Yu C, Subler M, Rahmani M, Reese E, Krystal G, Conrad D, Dent P, Grant S. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biology & Therapy. 2: 544-51. PMID 14614324 DOI: 10.4161/Cbt.2.5.454 |
0.583 |
|
| 2003 |
Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process Oncogene. 22: 7108-7122. PMID 14562039 DOI: 10.1038/sj.onc.1206863 |
0.499 |
|
| 2003 |
Litz J, Carlson P, Warshamana-Greene GS, Grant S, Krystal GW. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4586-94. PMID 14555534 |
0.37 |
|
| 2003 |
Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia. 17: 2036-45. PMID 14513055 DOI: 10.1038/sj.leu.2403109 |
0.428 |
|
| 2003 |
Yacoub A, Mitchell C, Lebedeva IV, Sarkar D, Su ZZ, McKinstry R, Gopalkrishnan RV, Grant S, Fisher PB, Dent P. mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling. Cancer Biology & Therapy. 2: 347-53. PMID 14508103 DOI: 10.4161/Cbt.2.4.422 |
0.497 |
|
| 2003 |
Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P, Grant S. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene. 22: 6231-42. PMID 13679862 DOI: 10.1038/Sj.Onc.1206646 |
0.824 |
|
| 2003 |
Dai Y, Rahmani M, Grant S. An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells Cell Cycle (Georgetown, Tex.). 2: 467-472. PMID 12963846 |
0.347 |
|
| 2003 |
Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene. 22: 5885-96. PMID 12947395 DOI: 10.1038/Sj.Onc.1206701 |
0.42 |
|
| 2003 |
Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 102: 3765-74. PMID 12893773 DOI: 10.1182/Blood-2003-03-0737 |
0.51 |
|
| 2003 |
Yacoub A, Mitchell C, Brannon J, Rosenberg E, Qiao L, McKinstry R, Linehan WM, Su ZS, Sarkar D, Lebedeva IV, Valerie K, Gopalkrishnan RV, Grant S, Fisher PB, Dent P. MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. Molecular Cancer Therapeutics. 2: 623-32. PMID 12883035 |
0.347 |
|
| 2003 |
Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research. 63: 3637-45. PMID 12839953 |
0.38 |
|
| 2003 |
Decker RH, Levin J, Kramer LB, Dai Y, Grant S. Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis. Biochemical Pharmacology. 65: 1997-2008. PMID 12787880 DOI: 10.1016/S0006-2952(03)00149-7 |
0.574 |
|
| 2003 |
Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, Grant S. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood. 102: 1824-32. PMID 12738674 DOI: 10.1182/Blood-2002-12-3785 |
0.572 |
|
| 2003 |
Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Research. 63: 2118-26. PMID 12727828 |
0.517 |
|
| 2003 |
Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Research. 63: 1822-33. PMID 12702569 |
0.496 |
|
| 2003 |
Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, Amorino G, Valerie K, Sealy L, Engelhardt JF, Grant S, Hylemon PB, Dent P. Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Molecular and Cellular Biology. 23: 3052-66. PMID 12697808 DOI: 10.1128/Mcb.23.9.3052-3066.2003 |
0.429 |
|
| 2003 |
Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biology & Therapy. 2: 30-7. PMID 12673114 DOI: 10.4161/cbt.190 |
0.411 |
|
| 2003 |
Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 6: 15-26. PMID 12654284 DOI: 10.1016/S1368-7646(02)00141-3 |
0.421 |
|
| 2003 |
Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ullrich R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiation Research. 159: 283-300. PMID 12600231 DOI: 10.1667/0033-7587(2003)159[0283:Sariao]2.0.Co;2 |
0.41 |
|
| 2003 |
Cartee L, Maggio SC, Smith R, Sankala HM, Dent P, Grant S. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol Molecular Cancer Therapeutics. 2: 83-93. PMID 12533676 |
0.492 |
|
| 2003 |
Wang S, Wang Z, Dent P, Grant S. Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells. Blood. 101: 3648-57. PMID 12522001 DOI: 10.1182/Blood-2002-09-2739 |
0.597 |
|
| 2003 |
Wang S, Wang Z, Grant S. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Molecular Pharmacology. 63: 232-42. PMID 12488556 DOI: 10.1124/Mol.63.1.232 |
0.584 |
|
| 2003 |
Dai Y, Rahmani M, Grant S. An Intact NF-kappaB Pathway is Required for Histone Deacetylase Inhibitor Induced G1 Arrest and Maturation in U937 Human Myeloid Leukemia Cells Cell Cycle. 2: 465-470. DOI: 10.4161/Cc.2.5.465 |
0.484 |
|
| 2002 |
Yu C, Dai Y, Dent P, Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to STI571 Cancer Biology and Therapy. 1: 674-682. PMID 12642693 DOI: 10.4161/Cbt.319 |
0.53 |
|
| 2002 |
Grant S, Dent P. Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors Cell Cycle (Georgetown, Tex.). 1: 383-388. PMID 12548009 DOI: 10.4161/Cc.1.6.260 |
0.467 |
|
| 2002 |
Grant S, Fisher PB, Dent P. The role of signal transduction pathways in drug and radiation resistance Cancer Treatment and Research. 112: 89-108. PMID 12481713 DOI: 10.1007/978-1-4615-1173-1_5 |
0.377 |
|
| 2002 |
Rosato RR, Almenara JA, Cartee L, Betts V, Chellappan SP, Grant S. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Molecular Cancer Therapeutics. 1: 253-66. PMID 12467221 |
0.453 |
|
| 2002 |
McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, Hagan MP, Grant S, Dent P. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biology & Therapy. 1: 243-53. PMID 12432271 DOI: 10.4161/Cbt.75 |
0.696 |
|
| 2002 |
Rahmani M, Grant S. UCN-01 (7-hydroxystauorsporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937) Cell Cycle (Georgetown, Tex.). 1: 273-281. PMID 12429947 DOI: 10.4161/cc.1.4.137 |
0.507 |
|
| 2002 |
Dai Y, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A Cell Cycle (Georgetown, Tex.). 1: 143-152. PMID 12429924 |
0.492 |
|
| 2002 |
Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood. 100: 3333-43. PMID 12384435 DOI: 10.1182/Blood-2002-03-0940 |
0.561 |
|
| 2002 |
Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells Clinical Cancer Research. 8: 2976-2984. PMID 12231544 |
0.505 |
|
| 2002 |
Qiao L, Yacoub A, McKinstry R, Park JS, Caron R, Fisher PB, Hagan MP, Grant S, Dent P. Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms. Cancer Biology & Therapy. 1: 168-76. PMID 12170777 DOI: 10.4161/Cbt.64 |
0.486 |
|
| 2002 |
Decker RH, Wang S, Dai Y, Dent P, Grant S. Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biology & Therapy. 1: 136-44. PMID 12170773 DOI: 10.4161/Cbt.58 |
0.74 |
|
| 2002 |
Cartee L, Sankala H, Davis C, Smith R, Maggio S, Lin PS, Dent P, Grant S. 7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism. International Journal of Oncology. 21: 351-9. PMID 12118331 |
0.413 |
|
| 2002 |
Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia. 16: 1331-43. PMID 12094258 DOI: 10.1038/sj.leu.2402535 |
0.486 |
|
| 2002 |
McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 100: 627-34. PMID 12091357 DOI: 10.1182/Blood-2002-01-0098 |
0.342 |
|
| 2002 |
Qiao L, McKinstry R, Gupta S, Gilfor D, Windle JJ, Hylemon PB, Grant S, Fisher PB, Dent P. Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology (Baltimore, Md.). 36: 39-48. PMID 12085347 DOI: 10.1053/Jhep.2002.33899 |
0.363 |
|
| 2002 |
Rahmani M, Dai Y, Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-α-mediated process Experimental Cell Research. 277: 31-47. PMID 12061815 DOI: 10.1006/excr.2002.5548 |
0.469 |
|
| 2002 |
Cartee L, Smith R, Dai Y, Rahmani M, Rosato R, Almenara J, Dent P, Grant S. Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Molecular Pharmacology. 61: 1313-21. PMID 12021392 DOI: 10.1124/Mol.61.6.1313 |
0.492 |
|
| 2002 |
Wang Z, Wang S, Dai Y, Grant S. Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L). The Journal of Pharmacology and Experimental Therapeutics. 301: 568-77. PMID 11961058 DOI: 10.1124/Jpet.301.2.568 |
0.549 |
|
| 2002 |
Qiao L, Yacoub A, Studer E, Gupta S, Pei XY, Grant S, Hylemon PB, Dent P. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology (Baltimore, Md.). 35: 779-89. PMID 11915023 DOI: 10.1053/Jhep.2002.32533 |
0.526 |
|
| 2002 |
Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival Frontiers in Bioscience : a Journal and Virtual Library. 7. PMID 11815285 DOI: 10.2741/Grant |
0.341 |
|
| 2002 |
Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Research. 62: 188-99. PMID 11782377 |
0.451 |
|
| 2002 |
Rahmani M, Grant S. UCN-01 (7-Hydroxystauorsporine) Blocks PMA-Induced Maturation and Reciprocally Promotes Apoptosis in Human Myelomonocytic Leukemia Cells (U937) Cell Cycle. 1: 279-287. DOI: 10.4161/Cc.1.4.138 |
0.564 |
|
| 2002 |
Dai Y, Dent P, Grant S. Induction of Apoptosis in Human Leukemia Cells by the CDK1 Inhibitor Cell Cycle. 1: 128-137. DOI: 10.4161/Cc.1.2.116 |
0.558 |
|
| 2002 |
Cartee L, Sankala H, Davis C, Smith R, Maggio S, Lin P, Dent P, Grant S. 7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism. International Journal of Oncology. 21: 351-359. DOI: 10.3892/Ijo.21.2.351 |
0.508 |
|
| 2001 |
Rabah D, Grant S, Ma C, Conrad DH. Bryostatin-1 specifically inhibits in vitro IgE synthesis Journal of Immunology. 167: 4910-4918. PMID 11673496 DOI: 10.4049/Jimmunol.167.9.4910 |
0.333 |
|
| 2001 |
Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, Molkentin J, Schmidt-Ullrich R, Fisher PB, Grant S, Hylemon PB, et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: Inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis Molecular Biology of the Cell. 12: 2629-2645. PMID 11553704 DOI: 10.1091/Mbc.12.9.2629 |
0.675 |
|
| 2001 |
Yu C, Wang Z, Dent P, Grant S. MEK1/2 inhibitors promote ara-C-induced apoptosis but not loss of δψm HL-60 cells Biochemical and Biophysical Research Communications. 286: 1011-1018. PMID 11527401 DOI: 10.1006/Bbrc.2001.5513 |
0.372 |
|
| 2001 |
Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death and Differentiation. 8: 715-24. PMID 11464216 DOI: 10.1038/sj.cdd.4400868 |
0.622 |
|
| 2001 |
Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A, Duigou GJ, Young CS, Grant S, Hagan MP, Ellis E, Fisher PB, Dent P. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene. 20: 3266-80. PMID 11423976 DOI: 10.1038/Sj.Onc.1204258 |
0.311 |
|
| 2001 |
Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). International Journal of Oncology. 19: 181-91. PMID 11408941 DOI: 10.3892/ijo.19.1.181 |
0.496 |
|
| 2001 |
Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Molecular Pharmacology. 60: 143-54. PMID 11408609 DOI: 10.1124/Mol.60.1.143 |
0.626 |
|
| 2001 |
Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P, Grant S. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Research. 61: 2583-91. PMID 11289135 |
0.688 |
|
| 2001 |
Vrana JA, Grant S. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. Blood. 97: 2105-14. PMID 11264178 DOI: 10.1182/blood.V97.7.2105 |
0.509 |
|
| 2000 |
Cartee L, Davis C, Lin PS, Grant S. Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism International Journal of Radiation Biology. 76: 1323-1333. PMID 11057740 DOI: 10.1080/09553000050151592 |
0.492 |
|
| 2000 |
Tang L, Boise LH, Dent P, Grant S. Potentiation of 1-β-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) Biochemical Pharmacology. 60: 1445-1456. PMID 11020446 DOI: 10.1016/S0006-2952(00)00463-9 |
0.435 |
|
| 2000 |
Wang Z, Wang S, Fisher PB, Dent P, Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine. Differentiation; Research in Biological Diversity. 66: 1-13. PMID 10997587 DOI: 10.1046/J.1432-0436.2000.066001001.X |
0.634 |
|
| 2000 |
Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Investigational New Drugs. 17: 227-40. PMID 10665476 DOI: 10.1023/A:1006328303451 |
0.417 |
|
| 1999 |
Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene. 18: 7016-25. PMID 10597302 DOI: 10.1038/Sj.Onc.1203176 |
0.7 |
|
| 1999 |
Wang S, Wang Z, Boise LH, Dent P, Grant S. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia. 13: 1564-73. PMID 10516758 DOI: 10.1038/Sj.Leu.2401532 |
0.635 |
|
| 1999 |
Vrana JA, Kramer LB, Saunders AM, Zhang XF, Dent P, Povirk LF, Grant S. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation. Biochemical Pharmacology. 58: 121-31. PMID 10403525 DOI: 10.1016/S0006-2952(99)00077-5 |
0.457 |
|
| 1999 |
Vrana JA, Wang Z, Rao AS, Tang L, Chen JH, Kramer LB, Grant S. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1. Leukemia. 13: 1046-55. PMID 10400420 DOI: 10.1038/sj.leu.2401454 |
0.454 |
|
| 1999 |
Wang S, Wang Z, Boise L, Dent P, Grant S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochemical and Biophysical Research Communications. 259: 67-72. PMID 10334917 DOI: 10.1006/Bbrc.1999.0669 |
0.636 |
|
| 1999 |
Vrana JA, Grant S, Dent P. Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation Radiation Research. 151: 559-569. PMID 10319729 DOI: 10.2307/3580032 |
0.516 |
|
| 1998 |
Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; A potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity Leukemia. 12: 1843-1850. PMID 9844914 DOI: 10.1038/Sj.Leu.2401222 |
0.356 |
|
| 1998 |
Jarvis WD, Fornari FA, Tombes RM, Erukulla RK, Bittman R, Schwartz GK, Dent P, Grant S. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-β-D- arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling Molecular Pharmacology. 54: 844-856. PMID 9804619 DOI: 10.1124/Mol.54.5.844 |
0.382 |
|
| 1998 |
Wang S, Guo CY, Castillo A, Dent P, Grant S. Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochemical Pharmacology. 56: 635-44. PMID 9783732 DOI: 10.1016/S0006-2952(98)00188-9 |
0.638 |
|
| 1998 |
Wang Z, Su ZZ, Fisher PB, Wang S, VanTuyle G, Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells. Experimental Cell Research. 244: 105-16. PMID 9770354 DOI: 10.1006/Excr.1998.4191 |
0.641 |
|
| 1998 |
Vrana JA, Saunders AM, Chellappan SP, Grant S. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation; Research in Biological Diversity. 63: 33-42. PMID 9615391 DOI: 10.1046/J.1432-0436.1998.6310033.X |
0.547 |
|
| 1998 |
Vrana JA, Rao AS, Wang Z, Jarvis WD, Grant S. Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure. International Journal of Oncology. 12: 927-34. PMID 9499457 DOI: 10.3892/ijo.12.4.927 |
0.365 |
|
| 1998 |
Jarvis WD, Fornari FA, Auer KL, Freemerman AJ, Szabo E, Birrer MJ, Johnson CR, Barbour SE, Dent P, Grant S. Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Molecular Pharmacology. 52: 935-47. PMID 9415703 DOI: 10.1124/mol.52.6.935 |
0.403 |
|
| 1997 |
Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Molecular Pharmacology. 52: 1000-9. PMID 9396780 DOI: 10.1124/Mol.52.6.1000 |
0.623 |
|
| 1997 |
Chelliah J, Freemerman AJ, Wu-Pong S, Jarvis WD, Grant S. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc Biochemical Pharmacology. 54: 563-573. PMID 9337072 DOI: 10.1016/S0006-2952(97)00212-8 |
0.333 |
|
| 1997 |
Jarvis WD, Auer KL, Spector M, Kunos G, Grant S, Hylemon P, Mikkelsen R, Dent P. Positive and negative regulation of JNK1 by protein kinase C and p42(MAP kinase) in adult rat hepatocytes. Febs Letters. 412: 9-14. PMID 9257680 DOI: 10.1016/S0014-5793(97)00705-9 |
0.349 |
|
| 1997 |
Grant S. Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1 Frontiers in Bioscience : a Journal and Virtual Library. 2. PMID 9195893 |
0.435 |
|
| 1997 |
Freemerman AJ, Vrana JA, Tombes RM, Jiang H, Chellappan SP, Fisher PB, Grant S. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia. 11: 504-13. PMID 9096690 DOI: 10.1038/Sj.Leu.2400625 |
0.443 |
|
| 1996 |
Grant S, Turner AJ, Freemerman AJ, Wang Z, Kramer L, Jarvis WD. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis. Experimental Cell Research. 228: 65-75. PMID 8892972 DOI: 10.1006/excr.1996.0300 |
0.447 |
|
| 1996 |
Bear HD, Mcfadden AW, Kostuchenko PJ, Lipshy KA, Hamad GG, Turner AJ, Roberts JD, Carr M, Carr S, Grant S. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration. Anti-Cancer Drugs. 7: 299-306. PMID 8792004 DOI: 10.1097/00001813-199605000-00010 |
0.444 |
|
| 1996 |
Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Gewirtz DA. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin Biochemical Pharmacology. 51: 931-940. PMID 8651943 DOI: 10.1016/0006-2952(96)00050-0 |
0.359 |
|
| 1996 |
Jarvis WD, Fornari FA, Traylor RS, Martin HA, Kramer LB, Erukulla RK, Bittman R, Grant S. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. The Journal of Biological Chemistry. 271: 8275-84. PMID 8626522 DOI: 10.1074/Jbc.271.14.8275 |
0.394 |
|
| 1996 |
Watson NC, Jarvis WD, Orr MS, Grant S, Gewirtz DA. Radiosensitization of HL-60 human leukaemia cells by bryostatin-1 in the absence of increased DNA fragmentation or apoptotic cell death. International Journal of Radiation Biology. 69: 183-92. PMID 8609454 DOI: 10.1080/095530096146011 |
0.311 |
|
| 1994 |
Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proceedings of the National Academy of Sciences of the United States of America. 91: 73-7. PMID 8278410 DOI: 10.1073/Pnas.91.1.73 |
0.405 |
|
| 1993 |
Bhalla K, Ibrado A, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney M. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells Blood. 82: 3133-3140. DOI: 10.1182/blood.v82.10.3133.bloodjournal82103133 |
0.442 |
|
| 1992 |
Grant S, Jarvis WD, Turner AJ, Wallace HJ, Pettit GR. Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-beta-D-arabinofuranosylcytosine in human leukaemic myeloblasts. British Journal of Haematology. 82: 522-8. PMID 1486032 DOI: 10.1111/J.1365-2141.1992.Tb06462.X |
0.379 |
|
| 1992 |
Bhalla K, Tang C, Ibrado A, Grant S, Tourkina E, Holladay C, Hughes M, Mahoney M, Huang Y. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells Blood. 80: 2883-2890. DOI: 10.1182/Blood.V80.11.2883.Bloodjournal80112883 |
0.404 |
|
| 1991 |
Grant S, Bhalla K, McCrady C. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Leukemia Research. 15: 205-13. PMID 2030601 DOI: 10.1016/0145-2126(91)90122-A |
0.409 |
|
| 1991 |
McCrady CW, Staniswalis J, Pettit GR, Howe C, Grant S. Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF. British Journal of Haematology. 77: 5-15. PMID 1998597 DOI: 10.1111/J.1365-2141.1991.Tb07941.X |
0.379 |
|
| 1991 |
Grant S, Boise L, Westin E, Howe C, Pettit GR, Turner A, McCrady C. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Biochemical Pharmacology. 42: 853-67. PMID 1867641 DOI: 10.1016/0006-2952(91)90046-8 |
0.335 |
|
| 1990 |
Bhalla KN, Gongrong L, Grant S, Cole JT, MacLaughlin WW, Volsky DJ. The effect in vitro of 2′-deoxycytidine on the metabolism and cytotoxicity of 2′,3′-dideoxycytidine Aids. 4: 427-431. PMID 2115341 DOI: 10.1097/00002030-199005000-00008 |
0.359 |
|
| 1987 |
Bhalla K, Grant S. Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis. Cancer Chemotherapy and Pharmacology. 19: 226-32. PMID 3581416 DOI: 10.1007/BF00252977 |
0.316 |
|
| 1986 |
Fisher PB, Grant S, Greiner JW, Schlom J. Measurement of the effect of interferons on the proliferative capacity and cloning efficiency of normal and leukemic human myeloid progenitor cells in culture Methods in Enzymology. 629-634. PMID 2429159 DOI: 10.1016/0076-6879(86)19084-7 |
0.407 |
|
| 1986 |
Grant S, Bhalla K, Gleyzer M. Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells. Leukemia Research. 10: 1139-46. PMID 2429121 DOI: 10.1016/0145-2126(86)90059-7 |
0.329 |
|
| 1984 |
Bhalla K, Nayak R, Deitch A, Grant S. Synergistic interaction between acivicin (AT-125) and 6-thioguanine in the murine leukemia L1210. Biochemical and cytokinetic considerations. Biochemical Pharmacology. 33: 247-54. PMID 6200115 DOI: 10.1016/0006-2952(84)90482-9 |
0.402 |
|
| Show low-probability matches. |
